全文获取类型
收费全文 | 2319篇 |
免费 | 96篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 80篇 |
儿科学 | 139篇 |
妇产科学 | 92篇 |
基础医学 | 161篇 |
口腔科学 | 83篇 |
临床医学 | 203篇 |
内科学 | 501篇 |
皮肤病学 | 47篇 |
神经病学 | 120篇 |
特种医学 | 105篇 |
外科学 | 491篇 |
综合类 | 43篇 |
一般理论 | 1篇 |
预防医学 | 39篇 |
眼科学 | 90篇 |
药学 | 56篇 |
中国医学 | 7篇 |
肿瘤学 | 178篇 |
出版年
2024年 | 1篇 |
2023年 | 22篇 |
2022年 | 29篇 |
2021年 | 36篇 |
2020年 | 26篇 |
2019年 | 37篇 |
2018年 | 49篇 |
2017年 | 37篇 |
2016年 | 76篇 |
2015年 | 80篇 |
2014年 | 108篇 |
2013年 | 161篇 |
2012年 | 188篇 |
2011年 | 174篇 |
2010年 | 110篇 |
2009年 | 112篇 |
2008年 | 210篇 |
2007年 | 197篇 |
2006年 | 185篇 |
2005年 | 182篇 |
2004年 | 153篇 |
2003年 | 84篇 |
2002年 | 85篇 |
2001年 | 27篇 |
2000年 | 5篇 |
1999年 | 8篇 |
1998年 | 8篇 |
1997年 | 9篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1994年 | 3篇 |
1993年 | 5篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1981年 | 1篇 |
1978年 | 2篇 |
1975年 | 1篇 |
1960年 | 1篇 |
1955年 | 1篇 |
排序方式: 共有2436条查询结果,搜索用时 15 毫秒
31.
32.
33.
34.
Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Beh?et's disease.
下载免费PDF全文
![点击此处可从《Annals of the rheumatic diseases》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A Orem O De?er O Memi? S Bahadir E Ovali G Cim?it 《Annals of the rheumatic diseases》1995,54(9):726-729
OBJECTIVES--To investigate whether plasma levels of Lp(a) lipoprotein (Lp(a)) are predictors of defective fibrinolytic activity, leading to thrombosis, in patients with Behçet's disease. METHODS--Plasma Lp(a) was measured by enzyme linked immunosorbent assay, lipids and lipoproteins by enzymatic methods, and apolipoproteins A-I and B, fibrinogen (turbidimetric method), tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), and D-dimer levels by enzyme immunoassay. Their levels and interactions were evaluated in 33 patients with Behçet's disease (including five with thrombotic complications) and 30 healthy control subjects. RESULTS--Plasma Lp(a) concentration was significantly greater in the patients than in controls. Nine patients (27%) had levels > 0.30 microgram. There was no correlation between Lp(a) and other lipids and lipoproteins apart from apolipoprotein B. Lp(a) showed inverse correlation with t-PA (r = -0.34, p < 0.05) and D-dimer (r = 0.35, p < 0.05). Patients with thrombotic complications had significantly greater Lp(a) and PAI-1, and lower D-dimer concentrations than control subjects. CONCLUSIONS--Measurement of plasma Lp(a) levels in patients with Behçet's disease may provide useful information regarding the potential development of thrombotic events, because of its possible role in defective fibrinolysis. 相似文献
35.
36.
Efficacy and safety of pegylated-interferon α-2a in hemodialysis patients with chronic hepatitis C 总被引:5,自引:0,他引:5
AIM: To evaluate the efficacy and safety of pegylated- interferon alpha-2a in hemodialysis patients with chronic hepatitis C. METHODS: Thirty-six hemodialysis patients with chronic hepatitis C were enrolled in a controlled and prospective study. All patients were treatment naive, positive tested for anti-HCV antibodies, and positive tested for serum HCV-RNA. Twenty-two patients received 135 μg peglyated-interferon α-2a weekly for 48 wk (group A). The remaining patients were left untreated, eleven refused therapy, and three were not candidates for kidney transplantation and were allocated to the control group (group B). At the end of the treatment biochemical and virological response was evaluated, and 24 wk after completetion of therapy sustained virological response (SVR) was assessed. Side effects were monitored.
RESULTS: Of 22 hemodialysis patients, 12 were male and 10 female, with a mean age of 35.2 ± 12.1 years. Virological end-of-treatment response was observed in 14 patients (82.4%) in group A and in one patient (7.1%) in group B (P = 0.001). Sustained virological response was observed in 11 patients (64.7%) in group A and in one patient in group B (7.1%). Biochemical response parameters normalized in 10/14 patients (71.4%) at the end of the treatment. ALT levels in group B were initially high in six patients and normalized in one of them (25%) at the end of the 48 wk. In five patients (22.7%) therapy had to be stopped at mo 4 due to complications of weakness, anemia, and bleeding.
CONCLUSION: SVR could be achieved in 64.7% of patients on hemodialysis with chronic hepatitis C by a treatment with peglyated-interferon α-2a. Group A had a significantly better efficacy compared to the control group B, but the side effects need to be concerned. 相似文献
RESULTS: Of 22 hemodialysis patients, 12 were male and 10 female, with a mean age of 35.2 ± 12.1 years. Virological end-of-treatment response was observed in 14 patients (82.4%) in group A and in one patient (7.1%) in group B (P = 0.001). Sustained virological response was observed in 11 patients (64.7%) in group A and in one patient in group B (7.1%). Biochemical response parameters normalized in 10/14 patients (71.4%) at the end of the treatment. ALT levels in group B were initially high in six patients and normalized in one of them (25%) at the end of the 48 wk. In five patients (22.7%) therapy had to be stopped at mo 4 due to complications of weakness, anemia, and bleeding.
CONCLUSION: SVR could be achieved in 64.7% of patients on hemodialysis with chronic hepatitis C by a treatment with peglyated-interferon α-2a. Group A had a significantly better efficacy compared to the control group B, but the side effects need to be concerned. 相似文献
37.
Zehra Narli Ozdemir Guldane Cengiz Seval Ugur Sahin Atilla Uslu Mehmet Gunduz Sinem Civriz Bozdag Selami Kocak Toprak Meltem Kurt Yuksel Pervin Topcuoglu Isinsu Kuzu Muhit Ozcan Gunhan Gurman Osman Ilhan 《Indian journal of hematology & blood transfusion》2021,37(1):67
PurposeBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and poor prognostic hematological malignancy. There is still no standard treatment established for BPDCN patients. We aim to summarize the main clinical, biological features and treatment of 9 BPDCN patients.MethodsNine patients with BPDCN who had been diagnosed between July 2008 and December 2018 in Ankara University School of Medicine, were retrospectively evaluated.ResultsAll patients (n = 9) were male, median age was 64 (21–80). Five patients (55.6%) had bone marrow infiltration, 5 patients (55.6%) cutaneous lesions, 6 patients (66.7%) lymph node involvement, 2 patients (22.2%) central nervous system involvement and 2 patients (22.2%) spleen involvement at time of diagnosis. Complex karyotype was observed in 2 patients. CHOP was given to 5 patients (55.6%), hyper-CVAD to 2 patients (22.2%), fludarabine, cyclophosphamide and mitoxantrone to 1 patient (11.1%) and cyclophosphamide, etoposide, methylprednisolone to 1 patient (11.1%) as first line chemotherapy. Four patients (44.4%) underwent allogeneic hematopoietic stem cell transplantation (AHSCT) in complete remission (CR) 1. Venetoclax was given to a transplant ineligible patient who had skin and lymph node involvement, with the off-label use. The median follow-up time was 15.9 months (3–48.6 months). Estimated median overall survival was 15.9 + 1.6 (95% CI 12.7–19.1) months.ConclusionIntensive induction therapies followed by AHSCT in CR seems to be best approaches for patients with BPDCN. Thus, more effective treatment strategies particularly targeted therapies should be warranted to improve the survival of patients with this rare disease. 相似文献
38.
39.
40.
Ugur Ozerdem Eva M. WojcikGüliz A. Barkan Xiuzhen DuanÇağatay Erşahin 《Pathology, research and practice》2013